Drug intelligence / Profile preview

GAIA-251

Development stage: Preclinical
Lead developer: GAIA BioMedicine
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

GAIA-251 is a preclinical-stage chimeric antigen receptor (CAR)-modified natural killer (NK)-like cell therapy being developed by GAIA BioMedicine. The therapy is produced using GAIA's proprietary NK-like cell platform, with cells derived from embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs). These cells are engineered with a CAR to redirect their innate cytotoxicity toward specific, though currently undisclosed, tumor-associated antigens. GAIA-251 is intended for intravenous administration for the treatment of various cancers, although specific indications have not yet been announced.

Beyond the preview

Go deeper on GAIA-251.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GAIA-251.

Explore the full profile